IGF2BP2 and acute lymphoblastic leukemia: Similarly, the IGF2BP2 overexpression decreased Ara-C-, VCR-,venetoclax- and Dex-induced cell apoptosis (Fig. 2D & Supplementary Fig. 4F), confirming that IGF2BP2 could promote T-ALL resistant to chemotherapeutics, including Ara-C, Dex, VCR and venetoclax.